Thalys Medical Technology Group

Thalys Medical Technology Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Thalys Medical Technology Group (603716.SS) as of Oct 29, 2026 is 20.97 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -36.51 % — a change of -157.45% (higher).

FCF Conversion

20.97 %

YoY

-157.45%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Thalys Medical Technology Group is 2025 20.97 % . FCF Conversion Rate (FCF/EBITDA) of Thalys Medical Technology Group was 2024 -36.51 % . It decreases by -157.45% higher compared to the previous year.

The Thalys Medical Technology Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-193.69 CNY
Jan 1, 2019
-2.33 CNY
Jan 1, 2020
-204.58 CNY
Jan 1, 2021
391.29 CNY
Jan 1, 2022
17.25 CNY
Jan 1, 2023
-53.64 CNY
Jan 1, 2024
-36.51 CNY
Jan 1, 2025
20.97 CNY
The Thalys Medical Technology Group FCF Conversion history
YEARFCF ConversionYoY
20.97 %-157.45%
-36.51 %-31.94%
-53.64 %-410.93%
17.25 %-95.59%
391.29 %-291.27%
-204.58 %+8,698.59%
-2.33 %-98.80%
-193.69 %+1.40%
-191.01 %+52.98%
-124.86 %-1,461.11%
9.17 %-410.90%
-2.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Thalys Medical Technology Group Stock analysis

What does Thalys Medical Technology Group do? Thalys Medical Technology Group Corp, based in Wuhan, China, operates in the Health Care sector with a focus on Biotechnology. The company develops, produces, and sells in vitro diagnostic products, including reagents, consumables, and equipment. It serves major domestic markets such as Hubei, Hunan, Jiangsu, Henan, and Shanghai, employing 1,474 full-time staff. Listed on October 31, 2016, Thalys specializes in diagnostic solutions for the Chinese healthcare market. Thalys Medical Technology Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Thalys Medical Technology Group stock

FCF Conversion Rate (FCF/EBITDA) of Thalys Medical Technology Group is 20.97 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Thalys Medical Technology Group changed from -36.51 % to 20.97 %, representing a -157.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Thalys Medical Technology Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Thalys Medical Technology Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Thalys Medical Technology Group

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Thalys Medical Technology Group